Results of a Phase II study suggest that romosozumab significantly increases bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck. Exploratory analyses showed the BMD increases in the lumbar spine and hip were significantly higher with romosozumab than alendronate sodium and teriparatide in postmenopausal women with low BMD.
Results of a Phase II study suggest that romosozumab significantly increases bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck. Exploratory analyses showed the BMD increases in the lumbar spine and hip were significantly higher with romosozumab than alendronate sodium and teriparatide in postmenopausal women with low BMD.
Researchers from the Oregon Osteoporosis Center evaluated the efficacy of romosozumab for a 12-month period in 419 women aged 55 to 85 years of age who had low BMD (T score -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the 3 sites). Participants were randomly assigned to monthly romosozumab (a dose of 70 mg, 140 mg, or 210 mg) or romosozumab every 3 months (a dose of 140 mg or 210 mg) administered subcutaneously; subcutaneous placebo; or an open-label active comparator – oral alendronate (70 mg) administered weekly or subcutaneous teriparatide (20 μg) administered daily.
The investigators found that all dosage levels of romosozumab were associated with significant BMD increases at the lumbar spine, an increase of 11.3% with the 210 mg monthly dose. In comparison, teriparatide resulted in an increase of 7.1% and alendronate in an increase of 4.1%. BMD decreased 0.1% in the comparator group. Romosozumab was also associated with significant increases in BMD at the total hip and femoral neck, transitory increases in bone-formation markers, and sustained descreases in a bone-resorption marker. Adverse effects were mild across all dosage groups, with the most common being mild, generally nonrecurring injection-site reactions.
The scientists concluded that romosozumab was associated with increased BMD and bone formation in postmenopausal women.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Peer support programs: A powerful solution to alleviate physician burnout
December 6th 2023Discover how the implementation of peer support initiatives, such as the successful Peer Outreach Support Team, is revolutionizing healthcare culture, reducing burnout rates, and fostering positive changes among physicians.
Read More
Link between infertility and autism spectrum disorder risk
December 6th 2023New research uncovers a connection between infertility and autism spectrum disorder risk, prompting a closer look at perinatal influences and the potential impact of fertility treatments on the developmental trajectory of children.
Read More
A study reveals how personalized digital health tools, such as a Digital Personal Health Librarian, leveraging electronic health records, social data, and advanced technologies, can not only enhance wellness care and preventive health but also significantly improve the uptake of interventions like HPV vaccination.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More